Boston Common Asset Management LLC Acquires 9,028 Shares of Edwards Lifesciences Corporation $EW

Boston Common Asset Management LLC boosted its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 6.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 144,703 shares of the medical research company’s stock after buying an additional 9,028 shares during the quarter. Boston Common Asset Management LLC’s holdings in Edwards Lifesciences were worth $12,336,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of EW. Fjarde AP Fonden Fourth Swedish National Pension Fund increased its holdings in Edwards Lifesciences by 7.0% during the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 137,835 shares of the medical research company’s stock valued at $10,719,000 after buying an additional 9,069 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Edwards Lifesciences by 13.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,235 shares of the medical research company’s stock worth $6,706,000 after acquiring an additional 10,078 shares during the period. Atlantic Union Bankshares Corp boosted its stake in shares of Edwards Lifesciences by 2,240.9% during the 3rd quarter. Atlantic Union Bankshares Corp now owns 11,892 shares of the medical research company’s stock worth $925,000 after acquiring an additional 11,384 shares during the last quarter. Washington Trust Advisors Inc. grew its position in shares of Edwards Lifesciences by 15.6% during the 3rd quarter. Washington Trust Advisors Inc. now owns 130,587 shares of the medical research company’s stock valued at $10,156,000 after acquiring an additional 17,625 shares during the period. Finally, OMERS ADMINISTRATION Corp grew its position in shares of Edwards Lifesciences by 97.3% during the 2nd quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company’s stock valued at $3,481,000 after acquiring an additional 21,950 shares during the period. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Up 0.2%

Shares of EW stock opened at $79.52 on Tuesday. Edwards Lifesciences Corporation has a 52-week low of $65.94 and a 52-week high of $87.89. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72. The firm has a market capitalization of $45.84 billion, a PE ratio of 43.45, a PEG ratio of 2.07 and a beta of 0.93. The stock has a fifty day simple moving average of $81.92 and a two-hundred day simple moving average of $81.71.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing the consensus estimate of $0.62 by ($0.04). The business had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. Edwards Lifesciences’s revenue was up 13.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. BTIG Research reaffirmed a “buy” rating and issued a $103.00 target price on shares of Edwards Lifesciences in a report on Wednesday, February 11th. The Goldman Sachs Group reissued a “buy” rating and set a $95.00 price target (down from $108.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Piper Sandler restated an “overweight” rating and issued a $100.00 price target (up from $98.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Citigroup reaffirmed a “buy” rating and issued a $101.00 price objective (up from $96.00) on shares of Edwards Lifesciences in a research note on Thursday, December 11th. Finally, Stifel Nicolaus set a $110.00 price objective on Edwards Lifesciences and gave the company a “buy” rating in a research report on Tuesday, January 20th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $96.14.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $85.38, for a total value of $87,002.22. Following the transaction, the vice president directly owned 33,934 shares of the company’s stock, valued at approximately $2,897,284.92. The trade was a 2.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Scott B. Ullem sold 13,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $84.92, for a total value of $1,103,960.00. Following the completion of the transaction, the chief financial officer owned 39,699 shares of the company’s stock, valued at $3,371,239.08. The trade was a 24.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 61,718 shares of company stock valued at $5,236,281. Corporate insiders own 0.34% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.